| metastatic/adv melanoma (mML) | |||
| mML - L1 - all population | mML - L1 - BRAF mutant | mML - L1 - BRAF wild | |
| anti-PD-(L)1 | |||
| atezolizumab based treatment | |||
| atezolizumab plus cometinib | IMspire-170 | ||
| atezolizumab plus SoC | IMspire-150 ... | ||
| nivolumab based treatment | |||
| nivolumab alone | CheckMate 067 ... | CheckMate 066 | |
| nivolumab followed by ipilimumab | CheckMate 064 | ||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-